Effect of Buspirone in ADHD

Phase 2

Recruiting

• Conditions: Attention deficit/hyperactivity disorder.; Attention-deficit hyperactivity disorders

• Registration Number: IRCT20160530028182N7
• Lead Sponsor: Sanandaj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age between 6 -12 years
Diagnosis of ADHD and ODD based on DSM5
without effective medication taking on mental status at least 2 weeks before the study

Exclusion Criteria

Intelectual disability based on clinical suspicious
presence of uncontroled siezure
Drug side effects and hypersensivity
Recieving of any other drugs
History of psychological disorder except for ADHD and ODD
presence of medical deasese such as cardiac deaseses

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Profile of illness reported by parents. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Symptoms severity reported by parents. Timepoint: Baselin , second ,fourth and eighth weeks after intervention. Method of measurement: ADHD Rating scale and CGI.;Efficacy of treatment. Timepoint: Baselin , second ,fourth and eighth weeks after intervention. Method of measurement: The Clinical Global Impressions (CGI) Scale used to rate the symptoms change over time, and efficacy of medication, taking into account the patient’s clinical condition by clinicians.

Secondary Outcome Measures

Name	Time	Method
Drug side effects. Timepoint: Second, fourth and eighth weeks after intervention. Method of measurement: checklist by clinical interview and exam.